Managing Advanced Stages of Friedreich’s Ataxia: Challenges and Emerging Therapeutic Avenues : Episode 5
Opinion
Video
Examining Trial Data on Omaveloxolone Efficacy
A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.
- In 2023, a propensity matched comparison of MOXIe extension patients to an untreated cohort found a significant slowing of disease progression per mFARS of 3.0 points compared to 6.6 points, respectively. Are these results clinically meaningful for patients and how does this relate to your everyday clinical practice?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
